CompletedNCT00206141
Quetiapine compared with lithium for bipolar depression
Medication studyAges 18–65Multiple countriesBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Kelowna and 75 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 672
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada, Croatia, Estonia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00206141
- Official title
Show the full official title
Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Kelowna, Canada · Sydney, Canada · Greater Sudbury, Canada
74 more locations
- Markham, Canada
- Mississauga, Canada
- Orléans, Canada
- Waterloo, Canada
- Montreal, Canada
- Sherbrooke, Canada
- Osijek, Croatia
- Split, Croatia
- Zadar, Croatia
- Zagreb-Susedgrad, Croatia
- Kohtla-Järve, Estonia
- Tallinn, Estonia
- Tartu, Estonia
- Berlin, Germany
- Würzburg, Germany
- Solo, Indonesia
- Jakarta, Indonesia
- Lawang, Indonesia
- Daugavpils, Latvia
- Riga, Latvia
- Kaunas, Lithuania
- Šiauliai, Lithuania
- Vilnius, Lithuania
- Kuala Lumpur, Malaysia
- Kuching Sarawak, Malaysia
- Petaling Jaya, Malaysia
- Brattvåg, Norway
- Drammen, Norway
- Fredrikstad, Norway
- Mysen, Norway
- Paradis, Norway
- Davao City, Philippines
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Manila, Philippines
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdynia, Poland
- Leszno, Poland
- Lodz, Poland
- Skorzewo, Poland
- Wroclaw, Poland
- Zabrze, Poland
- Arkhangelsk, Russia
- Kazan', Russia
- Lipetsk, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Smolensk, Russia
- Stavropol, Russia
- Tver', Russia
- Yaroslavl, Russia
- Belgrade, Serbia
- Čačak, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Valjevo, Serbia
- Gyeonggi-do, South Korea
- Seoul, South Korea
- Changhua, Taiwan
- Taipei, Taiwan
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Luhansk, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Vinnitsa, Ukraine
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood).
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
